| http://www.w3.org/ns/prov#value | - A further list and description of these risks, uncertainties an...Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis...ts attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and g
|
